понедельник, 16 мая 2016 г.

Valeant's New CEO Changes Rebates for 2 Scrutinized Drugs

Valeant's New CEO Changes Rebates for 2 Scrutinized Drugs


Valeant Pharmaceuticals International Inc. adjusted hospital rebates for two heart drugs that were at the center of congressional investigations of price hikes, as new Chief Executive Joe Papa begins his attempt to turn around the company. In the plan unveiled on Monday, hospitals will get at least 10 percent off the list price of heart drugs Nitropress and Isuprel, up to 40 percent off based on volume.



from Biotech News